Testosterone Enanthate Manufacturing, Supply & Shortage History

How Testosterone Enanthate Is Manufactured

Testosterone enanthate production begins with the synthesis of the active pharmaceutical ingredient (API) through esterification of testosterone with enanthoic acid (heptanoic acid). This reaction attaches a 7-carbon fatty acid chain to the 17-beta hydroxyl group of the testosterone molecule, creating the slow-release depot characteristic that allows weekly or biweekly dosing [1].

The API manufacturing process involves multiple steps: microbial fermentation or chemical synthesis of the testosterone base, purification to pharmaceutical grade, esterification under controlled conditions, and final crystallization. Global API production concentrates in facilities across India (Symbiotec Pharmalab, Jayco Chemical Industries) and China, where regulatory inspections by the FDA occur on a rotating basis every 2-3 years [2]. This geographic concentration creates vulnerability. When the FDA issued warning letters to two major Indian API suppliers in 2018, downstream finished-dose manufacturers in the U.S. and Europe experienced raw material delays within 60-90 days.

Finished dosage form production (the sterile oil-based injectable solution) requires aseptic manufacturing capability. The testosterone enanthate powder is dissolved in a carrier oil (typically cottonseed or sesame oil), combined with a preservative (chlorobutanol or benzyl alcohol), filtered through 0.22-micron sterilization filters, and filled into vials under ISO Class 5 cleanroom conditions [3]. Each batch undergoes sterility testing, endotoxin testing, potency assay, and particulate matter analysis before release.

The DEA Quota System and Its Supply Impact

Because testosterone is classified as a Schedule III controlled substance under the Controlled Substances Act, every milligram produced in or imported into the United States falls under the Drug Enforcement Administration's Aggregate Production Quota (APQ) system [4]. Each calendar year, the DEA sets a ceiling on total domestic testosterone production across all manufacturers.

The quota-setting process has repeatedly lagged behind clinical demand growth. In 2019, the DEA initially proposed reducing the testosterone APQ by 9%, citing concerns about diversion. After industry pushback documenting legitimate prescription growth, the agency revised its final quota upward. But the lag between quota proposal (typically August), final rule (December), and manufacturer production planning creates 4-6 month windows where supply uncertainty cascades through the chain.

Manufacturers must individually apply for their allocation within the APQ. A new market entrant cannot simply begin producing testosterone without first securing quota allocation, which typically requires 12-18 months of regulatory processing. This barrier to entry keeps the supplier base concentrated and limits the market's ability to self-correct during shortages.

U.S. Market Structure: Who Makes It

The U.S. testosterone enanthate injectable market is served by a small number of manufacturers, creating an oligopoly structure vulnerable to single-source disruption [5].

Pfizer's Depo-Testosterone (manufactured at its McPherson, Kansas facility) has held dominant market share since the brand's FDA approval in 1979. Hikma Pharmaceuticals (formerly West-Ward/Endo) produces the most widely dispensed generic. Padagis (formerly Perrigo's generic injectables division) and Sun Pharmaceutical also hold approved ANDAs. In practice, any given month may see only 2-3 of these manufacturers actively shipping product.

The concentration ratio matters clinically. When Pfizer experienced a manufacturing delay at its Kansas facility in late 2023, roughly 35% of national supply disappeared within weeks. Unlike oral generics where dozens of manufacturers compete, sterile injectable production requires specialized facilities that cost $50-200 million to build and 3-5 years to bring online [6].

Timeline of Major Shortages

The FDA Drug Shortage Database and American Society of Health-System Pharmacists (ASHP) have tracked testosterone enanthate availability disruptions across multiple episodes.

2014-2015: The first significant modern shortage occurred when Endo Pharmaceuticals (now Hikma) temporarily halted production for facility upgrades. Duration: approximately 5 months. Resolution came when Pfizer increased Depo-Testosterone output under its existing quota allocation [7].

2018-2019: FDA warning letters to API suppliers in Hyderabad, India created upstream disruption. Multiple finished-dose manufacturers reported inability to source compliant API. The shortage affected testosterone enanthate and cypionate simultaneously, lasting 7 months nationally. During this period, the Endocrine Society issued guidance recommending that clinicians avoid initiating new TRT patients on injectable formulations unless supply could be confirmed [8].

2020 (COVID-related): Pandemic disruptions to international shipping and API production created a 3-month period of spot shortages, though national supply never fully collapsed. Compounding pharmacies reported 40% increases in testosterone prescription volume during Q2 2020 [9].

2023-2024: The most severe shortage to date. Contributing factors included a Pfizer manufacturing pause, Hikma capacity constraints, record-high prescription volumes exceeding 4 million annual fills, and DEA quota allocation that failed to account for telehealth-driven demand growth. The FDA listed testosterone enanthate injection as "currently in shortage" from September 2023 through May 2024 [10].

Demand Growth: Why Supply Cannot Keep Pace

U.S. testosterone prescriptions have grown at approximately 12% compound annual growth rate since 2015, driven by three forces: expanded clinical guidelines recognizing hypogonadism in younger men, direct-to-consumer telehealth platforms offering TRT, and aging demographics [11].

The T-Trials (2016), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65+ with serum testosterone below 275 ng/dL, demonstrated that testosterone treatment improved sexual function, walking distance, and vitality scores over 12 months [12]. Publication of these results in the New England Journal of Medicine provided evidence supporting TRT in older men and contributed to prescription growth in subsequent years. Dr. Peter Snyder, the T-Trials principal investigator at the University of Pennsylvania, noted: "These trials showed benefits in domains that matter to older men, but also underscored that testosterone treatment is not without risk and requires monitoring."

The American Urological Association's 2018 guideline update further broadened the eligible population by recommending testosterone measurement in men with symptoms regardless of age, rather than restricting testing to those over 40 [13]. Combined with telehealth platforms that reduced barriers to diagnosis and prescribing, eligible patient volume surged past what the existing manufacturing base was designed to serve.

The Role of Compounding Pharmacies

During shortage periods, compounding pharmacies under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act have served as a pressure valve for TRT patients [14]. These pharmacies can legally produce testosterone enanthate injections using bulk API sourced from FDA-registered suppliers, without holding an individual ANDA.

503B outsourcing facilities (which can produce without patient-specific prescriptions and distribute to clinics) grew from approximately 60 registered entities in 2018 to over 120 by 2024. During the 2023-2024 shortage, the FDA exercised enforcement discretion by not pursuing action against 503B facilities producing testosterone injectables even when commercially available equivalents technically existed in limited quantities [15].

Quality concerns persist. A 2021 FDA survey of 503B outsourcing facilities found that 28% of sampled sterile injectables had at least one quality deficiency (subpotency, superpotency, or sterility concern) [16]. Clinicians directing patients toward compounding pharmacies during shortages should verify the facility's FDA inspection history and current compliance status.

International Supply Chain Vulnerabilities

The testosterone enanthate supply chain spans four continents. Raw steroid precursors (typically diosgenin from yams or stigmasterol from soy) originate in China and Mexico. API synthesis facilities concentrate in India's Hyderabad and Ahmedabad pharmaceutical corridors. Carrier oils (cottonseed, sesame) come from U.S. and South American agricultural sources. Final sterile fill occurs in the U.S., Ireland, or India depending on the manufacturer [17].

Dr. Erin Fox, Senior Director of Drug Information at the University of Utah Health and a leading expert on pharmaceutical shortages, has stated: "Injectable testosterone is a perfect storm for shortage risk. You have controlled substance quotas, concentrated API sourcing, sterile manufacturing requirements, and demand that grows 10-15 percent per year. The surprise is not that shortages happen, but that we ever have stable supply."

Each node introduces failure modes. Indian API facilities face monsoon-season logistics challenges. Chinese precursor suppliers are subject to environmental enforcement shutdowns. U.S. sterile fill capacity is shared across multiple drug products, so an unrelated recall (contamination in another product line) can displace testosterone from a production schedule for months [18].

FDA and Industry Responses to Recurring Shortages

The FDA has deployed several mechanisms to mitigate testosterone enanthate shortages, though none address the structural concentration issue.

Temporary importation allowances have permitted Canadian and European-manufactured testosterone products (identical formulations approved by Health Canada or EMA) to enter U.S. distribution during acute shortages. The FDA invoked this authority during the 2023-2024 event, allowing importation of testosterone enanthate from Bayer's European supply chain [19].

The 2020 CARES Act requires manufacturers to notify the FDA of anticipated supply disruptions 6 months in advance for drugs on the Essential Medicines List. Testosterone enanthate was added to this list in 2022. Early notification has not prevented shortages but has allowed the FDA to coordinate across manufacturers, shifting quota allocations to firms with available capacity [20].

Industry responses include Pfizer's announced $150 million investment in expanding its McPherson injectable capacity (expected completion 2027), and Hikma's qualification of a second API supplier to reduce single-source dependency. Two new ANDA applicants filed for testosterone enanthate injection in 2024, though FDA approval timelines for sterile injectables average 30-36 months from filing [21].

Clinical Implications for Prescribers and Patients

Supply instability requires clinicians managing TRT patients to maintain contingency planning. The Endocrine Society recommends that practices maintain awareness of current shortage status via the FDA Drug Shortage Database and ASHP shortage listings [22].

Switching between testosterone enanthate and testosterone cypionate during shortages is pharmacologically straightforward. Both esters produce equivalent steady-state serum testosterone levels at identical mg doses administered on identical schedules. A 2019 pharmacokinetic comparison (N=39) demonstrated bioequivalence at the 200 mg/mL concentration [23]. The cypionate ester has a marginally longer half-life (approximately 8 days vs. 4.5 days for enanthate), which some clinicians exploit by extending injection intervals from 7 to 10 days during supply-constrained periods.

Patients should be counseled against stockpiling, which worsens shortages for other patients, and instead maintain a 30-day buffer supply consistent with their prescription schedule. Multi-dose vials (5 mL, containing 1 to 000 mg total) are more supply-efficient than single-dose vials and experience less frequent shortages due to lower per-unit manufacturing burden [24].

For patients experiencing extended unavailability (>4 weeks), transdermal testosterone gel (AndroGel, Testim, generic) provides therapeutic continuity. Dose conversion follows the general principle that 50 mg/day transdermal gel approximates the steady-state testosterone achieved by 100 mg/week injectable, though individual absorption varies and serum levels should be confirmed at 2-4 weeks after switching [25].

What Structural Fixes Would Prevent Future Shortages

Three interventions could materially reduce testosterone enanthate shortage frequency. First, DEA quota reform: legislation introduced in 2024 (the Prescription Drug Shortage Prevention Act) would require the DEA to automatically increase quotas when the FDA lists a controlled substance as in shortage, removing the current months-long lag [26]. Second, domestic API manufacturing: the CHIPS-style incentives proposed for pharmaceutical manufacturing could make U.S.-based testosterone API synthesis economically viable, reducing dependence on 2-3 overseas facilities. Third, strategic buffer stocks: the proposal to create a public-private testosterone reserve (modeled on the Strategic National Stockpile's approach to critical antibiotics) remains under discussion at FDA but faces opposition from manufacturers concerned about price effects.

Until structural reforms materialize, the testosterone enanthate supply chain remains vulnerable to the same concentration risks that have produced shortages every 2-3 years since 2014. Patients initiating TRT should discuss supply contingency with their prescriber at treatment start, not after a shortage begins.